JP2015505959A - 癌を有する患者に治療を選択する方法 - Google Patents

癌を有する患者に治療を選択する方法 Download PDF

Info

Publication number
JP2015505959A
JP2015505959A JP2014545002A JP2014545002A JP2015505959A JP 2015505959 A JP2015505959 A JP 2015505959A JP 2014545002 A JP2014545002 A JP 2014545002A JP 2014545002 A JP2014545002 A JP 2014545002A JP 2015505959 A JP2015505959 A JP 2015505959A
Authority
JP
Japan
Prior art keywords
cancer
pi3k
treatment
inhibitor
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014545002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505959A5 (https=
Inventor
シャラット シン，
シャラット シン，
アン クーラー，
アン クーラー，
タニ アン ティー． リー，
タニ アン ティー． リー，
サスワティ ハズラール，
サスワティ ハズラール，
リチャード カークランド，
リチャード カークランド，
シンジュン リュー，
シンジュン リュー，
フィリップ キム，
フィリップ キム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Publication of JP2015505959A publication Critical patent/JP2015505959A/ja
Publication of JP2015505959A5 publication Critical patent/JP2015505959A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2014545002A 2011-12-05 2012-12-05 癌を有する患者に治療を選択する方法 Pending JP2015505959A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161567085P 2011-12-05 2011-12-05
US61/567,085 2011-12-05
US201261728748P 2012-11-20 2012-11-20
US61/728,748 2012-11-20
PCT/US2012/068005 WO2013086031A1 (en) 2011-12-05 2012-12-05 Method of therapy selection for patients with cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017191195A Division JP2018054614A (ja) 2011-12-05 2017-09-29 癌を有する患者に治療を選択する方法

Publications (2)

Publication Number Publication Date
JP2015505959A true JP2015505959A (ja) 2015-02-26
JP2015505959A5 JP2015505959A5 (https=) 2016-01-28

Family

ID=48574842

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014545002A Pending JP2015505959A (ja) 2011-12-05 2012-12-05 癌を有する患者に治療を選択する方法
JP2017191195A Pending JP2018054614A (ja) 2011-12-05 2017-09-29 癌を有する患者に治療を選択する方法
JP2019182229A Pending JP2020024210A (ja) 2011-12-05 2019-10-02 癌を有する患者に治療を選択する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017191195A Pending JP2018054614A (ja) 2011-12-05 2017-09-29 癌を有する患者に治療を選択する方法
JP2019182229A Pending JP2020024210A (ja) 2011-12-05 2019-10-02 癌を有する患者に治療を選択する方法

Country Status (4)

Country Link
US (1) US20140273006A1 (https=)
EP (1) EP2788752B1 (https=)
JP (3) JP2015505959A (https=)
WO (1) WO2013086031A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017065277A1 (ja) * 2015-10-14 2017-04-20 日東紡績株式会社 ２種のプロテインキナーゼの活性測定を用いる解析方法による、薬剤感受性ヒト細胞株の判定方法
JP2018517129A (ja) * 2015-04-21 2018-06-28 ジェネンテック， インコーポレイテッド 前立腺がんの分析のための組成物及び方法
JP2022505266A (ja) * 2018-10-18 2022-01-14 メディミューン，エルエルシー 癌患者の治療を決定する方法
JP2023022111A (ja) * 2017-06-22 2023-02-14 キャンブリッジ ライフ サイエンシーズ リミテッド 抗ｅｒｂｂ３抗体治療に対する食道癌の応答を予測する方法およびキット

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016502974A (ja) * 2012-12-07 2016-02-01 ザ ジェネラル ホスピタル コーポレイション Ｐｉ３ｋ／ａｋｔ阻害剤化合物とｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び高増殖性疾患の治療におけるその使用
MX2015010854A (es) * 2013-03-14 2016-07-20 Genentech Inc Combinaciones de un compuesto inhibidor de mek con un compuesto inhibidor de her3/egfr y metodos de uso.
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
EP3107578A2 (en) * 2014-02-20 2016-12-28 Merrimack Pharmaceuticals, Inc. Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
WO2016011558A1 (en) * 2014-07-23 2016-01-28 Ontario Institute For Cancer Research Systems, devices and methods for constructing and using a biomarker
CN107003300B (zh) * 2014-12-12 2020-02-07 凯尔科迪股份有限公司 测量erbb信号传导通路活性以诊断和治疗癌症患者的方法
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
HK1249866A1 (zh) * 2015-06-29 2018-11-16 豪夫迈‧罗氏有限公司 用他塞利昔布进行治疗的方法
KR20190015360A (ko) * 2016-05-31 2019-02-13 네스텍 소시에테아노님 Ｈｅｒ2 및 ｈｅｒ3 경로 아형 분류를 기반으로 한, 유방암 환자에 대한 약물 치료법의 선택 방법
US20180117029A1 (en) * 2016-11-03 2018-05-03 Beth Israel Deaconess Medical Center, Inc. Targeting Metabolic Vulnerability in Triple-Negative Breast Cancer
MX2019011769A (es) 2017-04-03 2019-11-07 Hoffmann La Roche Anticuerpos que se unen a steap-1.
KR102267593B1 (ko) * 2018-10-19 2021-06-21 주식회사 프로티나 Her2 및 her3의 헤테로다이머를 표적으로 하는 약물 및 이의 스크리닝 방법
CN111888487B (zh) * 2020-09-04 2022-05-17 山西医科大学 肿瘤靶向型光声成像引导多阶段治疗纳米探针及制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010533842A (ja) * 2007-07-13 2010-10-28 プロメテウス ラボラトリーズ インコーポレイテッド 抗体アレイを用いた肺癌治療のための薬剤選択
JP2011514522A (ja) * 2008-02-25 2011-05-06 プロメテウス ラボラトリーズ インコーポレイテッド 抗体に基づくアレイを用いた乳癌療法のための薬物選択
WO2011088149A2 (en) * 2010-01-12 2011-07-21 Prometheus Laboratories Inc. Methods for predicting response of triple-negative breast cancer to therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532138A (en) 1990-04-26 1996-07-02 Behringwerke Ag Method and kits for determining peroxidatively active catalysts
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
WO1995006877A1 (en) 1993-09-03 1995-03-09 Behringwerke Ag Fluorescent oxygen channeling immunoassays
AU2005265214A1 (en) * 2004-06-21 2006-01-26 Exelixis, Inc. P4HAS as modifiers of the IGFR pathway and methods of use
NZ575827A (en) 2006-09-21 2012-02-24 Prometheus Lab Inc Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
EP2235536A4 (en) * 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
NZ596468A (en) 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
JP5795311B2 (ja) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
DK2491385T3 (en) 2009-10-20 2017-08-28 Diatech Holdings Inc PROXIMITY-MEDIED ASSAYS FOR DETECTING ONCOGEN FUSION PROTEINS
US20110217701A1 (en) * 2010-03-03 2011-09-08 Carter Scott L Prognostic Marker for Endometrial Carcinoma
SG191230A1 (en) * 2010-12-23 2013-07-31 Nestec Sa Drug selection for malignant cancer therapy using antibody-based arrays
EP2681552A2 (en) * 2011-03-02 2014-01-08 Nestec S.A. Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010533842A (ja) * 2007-07-13 2010-10-28 プロメテウス ラボラトリーズ インコーポレイテッド 抗体アレイを用いた肺癌治療のための薬剤選択
JP2011514522A (ja) * 2008-02-25 2011-05-06 プロメテウス ラボラトリーズ インコーポレイテッド 抗体に基づくアレイを用いた乳癌療法のための薬物選択
WO2011088149A2 (en) * 2010-01-12 2011-07-21 Prometheus Laboratories Inc. Methods for predicting response of triple-negative breast cancer to therapy

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018517129A (ja) * 2015-04-21 2018-06-28 ジェネンテック， インコーポレイテッド 前立腺がんの分析のための組成物及び方法
JP2021073437A (ja) * 2015-04-21 2021-05-13 ジェネンテック， インコーポレイテッド 前立腺がんの分析のための組成物及び方法
JP7022191B2 (ja) 2015-04-21 2022-02-17 ジェネンテック， インコーポレイテッド 前立腺がんの分析のための組成物及び方法
WO2017065277A1 (ja) * 2015-10-14 2017-04-20 日東紡績株式会社 ２種のプロテインキナーゼの活性測定を用いる解析方法による、薬剤感受性ヒト細胞株の判定方法
JPWO2017065277A1 (ja) * 2015-10-14 2018-08-09 日東紡績株式会社 ２種のプロテインキナーゼの活性測定を用いる解析方法による、薬剤感受性ヒト細胞株の判定方法
US10724071B2 (en) 2015-10-14 2020-07-28 Nitto Boseki Co., Ltd. Method for determining drug-sensitive human cell lines by analysis method in which measurement of activity of two types of protein kinase is used
JP2023022111A (ja) * 2017-06-22 2023-02-14 キャンブリッジ ライフ サイエンシーズ リミテッド 抗ｅｒｂｂ３抗体治療に対する食道癌の応答を予測する方法およびキット
JP7411055B2 (ja) 2017-06-22 2024-01-10 キャンブリッジ ライフ サイエンシーズ リミテッド 抗ｅｒｂｂ３抗体治療に対する食道癌の応答を予測する方法およびキット
JP2022505266A (ja) * 2018-10-18 2022-01-14 メディミューン，エルエルシー 癌患者の治療を決定する方法

Also Published As

Publication number Publication date
EP2788752A4 (en) 2015-11-11
WO2013086031A1 (en) 2013-06-13
EP2788752A1 (en) 2014-10-15
EP2788752B1 (en) 2018-10-03
JP2018054614A (ja) 2018-04-05
US20140273006A1 (en) 2014-09-18
JP2020024210A (ja) 2020-02-13

Similar Documents

Publication Publication Date Title
EP2788752B1 (en) Method of therapy selection for patients with lung cancer
US10697967B2 (en) Methods for predicting response of triple-negative breast cancer to therapy
EP2694972B1 (en) Methods for predicting and improving the survival of gastric cancer patients
US10401364B2 (en) Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
US20120231965A1 (en) Drug selection for colorectal cancer therapy using antibody-based arrays
US10640830B2 (en) Drug selection for non-small cell lung cancer therapy
JP6478417B2 (ja) 大腸癌患者の生存を予測及び改善するための方法
US20160305944A1 (en) Polyp recurrence
WO2014122599A1 (en) Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
HK1178602B (en) Methods for predicting response of triple-negative breast cancer to therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170530

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170613